{"id":"mistletoe-extract","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Chills"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Flu-like symptoms"}]},"_chembl":{"chemblId":"CHEMBL2108766","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Mistletoe extract contains bioactive compounds (lectins, viscotoxins, polysaccharides) that enhance innate and adaptive immune responses against malignant cells. It is believed to work through multiple pathways including direct cytotoxic effects on tumor cells, increased production of cytokines like TNF-α and IL-6, and activation of dendritic cells and lymphocytes. The extract has been used in complementary oncology, particularly in European cancer treatment protocols.","oneSentence":"Mistletoe extract stimulates the immune system to recognize and attack cancer cells through activation of natural killer cells and other immune effectors.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:34:35.555Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Adjunctive treatment in various cancers (breast, colorectal, gastric, lung)"},{"name":"Quality of life improvement in cancer patients"}]},"trialDetails":[{"nctId":"NCT05726383","phase":"PHASE2","title":"Iscador® P (Mistletoe) Immunotherapy for Recurrent Osteogenic Sarcoma","status":"RECRUITING","sponsor":"Hackensack Meridian Health","startDate":"2024-05-14","conditions":"Osteogenic Sarcoma Recurrent","enrollment":32},{"nctId":"NCT02106572","phase":"PHASE3","title":"Therapeutic Instillation of Mistletoe","status":"ACTIVE_NOT_RECRUITING","sponsor":"Abnoba Gmbh","startDate":"2015-04","conditions":"Superficial Bladder Cancer","enrollment":548},{"nctId":"NCT06920810","phase":"PHASE4","title":"Viscum Album for TNBC on Adjuvant Pembrolizumab","status":"RECRUITING","sponsor":"Ilsan Cha hospital","startDate":"2025-03-19","conditions":"Breast Cancer, Triple Negative Breast Cancer","enrollment":40},{"nctId":"NCT06408688","phase":"PHASE4","title":"Safety and Modulation of Adaptive Immunity by Iscador® Qu Viscum Album Extract in Patients With Advanced, Recurrent or Metastatic Cancers Treated With Immune Checkpoint Inhibitors","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2024-06-24","conditions":"Advanced Solid Tumor","enrollment":100},{"nctId":"NCT02948309","phase":"PHASE3","title":"Mistletoe Therapy in Primary and Recurrent Inoperable Pancreatic Cancer","status":"COMPLETED","sponsor":"Karolinska University Hospital","startDate":"2016-06","conditions":"Pancreatic Cancer","enrollment":290},{"nctId":"NCT03051477","phase":"PHASE1","title":"Trial of Mistletoe Extract in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2017-03-01","conditions":"Solid Tumor","enrollment":21},{"nctId":"NCT04376931","phase":"PHASE1, PHASE2","title":"A Prospective Dose Finding Study of Iscador Infusion","status":"UNKNOWN","sponsor":"HaEmek Medical Center, Israel","startDate":"2020-12-01","conditions":"Advanced Cancer","enrollment":24},{"nctId":"NCT00176046","phase":"PHASE4","title":"Mistletoe Extract in Early or Advanced Breast Cancer, A Feasibility Study","status":"COMPLETED","sponsor":"Heidelberg University","startDate":"1999-05","conditions":"Metastatic Breast Cancer","enrollment":114},{"nctId":"NCT02007005","phase":"PHASE1, PHASE2","title":"Maximum Tolerable Concentration of abnobaVISCUM Fraxini Intravesically in Patients With Superficial Bladder Cancer","status":"COMPLETED","sponsor":"Abnoba Gmbh","startDate":"2004-01","conditions":"Superficial Bladder Cancer","enrollment":37},{"nctId":"NCT02191540","phase":"PHASE3","title":"Efficacy and Safety Study of Abnoba Viscum F 20mg in Malignant Pleural Effusion Patients","status":"COMPLETED","sponsor":"Abnoba Korea","startDate":"2011-01","conditions":"Malignant Pleural Effusion","enrollment":68},{"nctId":"NCT00052325","phase":"PHASE2","title":"Mistletoe in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Are Receiving Palliative Chemotherapy","status":"UNKNOWN","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2002-10","conditions":"Lung Cancer","enrollment":""},{"nctId":"NCT01448655","phase":"","title":"Iscador Qu as Supportive Treatment in Colorectal Cancer (Union International Cancer Control, UICC Stages II-IV)","status":"UNKNOWN","sponsor":"IFAG AG","startDate":"2010-09","conditions":"Colorectal Cancer","enrollment":300},{"nctId":"NCT01448668","phase":"","title":"Iscador Qu as Supportive Treatment in Pancreatic Cancer (Union for International Cancer Control, UICC Stages II-IV)","status":"UNKNOWN","sponsor":"IFAG AG","startDate":"2010-09","conditions":"Pancreas Cancer","enrollment":220},{"nctId":"NCT00049608","phase":"PHASE1","title":"Gemcitabine Combined With Mistletoe in Treating Patients With Advanced Solid Tumors","status":"TERMINATED","sponsor":"National Center for Complementary and Integrative Health (NCCIH)","startDate":"2002-07","conditions":"Breast Cancer, Colorectal Cancer, Lung Cancer","enrollment":51},{"nctId":"NCT01401075","phase":"PHASE4","title":"RCT With Adjuvant Mistletoe Treatment in Gastric Cancer Patients","status":"COMPLETED","sponsor":"Abnoba Gmbh","startDate":"2006-03","conditions":"Gastric Cancer","enrollment":32},{"nctId":"NCT00006354","phase":"PHASE1","title":"Mistletoe Lectin in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2000-08","conditions":"Unspecified Adult Solid Tumor, Protocol Specific","enrollment":41},{"nctId":"NCT00006477","phase":"PHASE1","title":"Mistletoe Lectin in Treating Patients With Refractory Advanced Solid Tumors","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2000-09","conditions":"Unspecified Adult Solid Tumor, Protocol Specific","enrollment":26},{"nctId":"NCT01527760","phase":"NA","title":"Effectiveness of Viscum Album Mother Tincture as an Anti-hypertensive in Essential Hypertension","status":"COMPLETED","sponsor":"Fr Muller Homoeopathic Medical College","startDate":"2011-02","conditions":"Hypertension","enrollment":37},{"nctId":"NCT00516022","phase":"PHASE2","title":"Mistletoe as Complementary Treatment in Patients With Advanced Non-small-cell Lung Cancer (NSCLC), Treated With Carboplatin/Gemcitabine Chemotherapy Combination.","status":"COMPLETED","sponsor":"Rambam Health Care Campus","startDate":"2007-04","conditions":"Non Small Cell Lung Cancer","enrollment":79},{"nctId":"NCT01378702","phase":"PHASE1","title":"Safety and Immunological Effects of Two Mistletoe Preparations in Healthy Volunteers","status":"COMPLETED","sponsor":"University Hospital Freiburg","startDate":"2008-01","conditions":"Healthy Volunteers","enrollment":71},{"nctId":"NCT00079794","phase":"PHASE2","title":"Iscar for Supplemental Care in Stage IV Lung Cancer","status":"COMPLETED","sponsor":"National Center for Complementary and Integrative Health (NCCIH)","startDate":"2001-09","conditions":"Lung Cancer","enrollment":36}],"_emaApprovals":[],"_faersSignals":[{"count":3,"reaction":"FATIGUE"},{"count":2,"reaction":"ANGINA PECTORIS"},{"count":2,"reaction":"ARTHRALGIA"},{"count":2,"reaction":"ASTHENIA"},{"count":2,"reaction":"CONSTIPATION"},{"count":2,"reaction":"DIARRHOEA"},{"count":2,"reaction":"GASTROINTESTINAL HAEMORRHAGE"},{"count":2,"reaction":"HEADACHE"},{"count":2,"reaction":"HYPOAESTHESIA"},{"count":2,"reaction":"INTERNATIONAL NORMALISED RATIO INCREASED"}],"_approvalHistory":[],"publicationCount":212,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["There's no drug to be administered in the control group.","abnobaVISCUM Quercus 0.02 mg","abnobaVISCUM Quercus 0.2 mg","abnobaVISCUM Quercus 2 mg","abnobaVISCUM Quercus 20 mg"],"phase":"marketed","status":"active","brandName":"Mistletoe extract","genericName":"Mistletoe extract","companyName":"Rambam Health Care Campus","companyId":"rambam-health-care-campus","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Mistletoe extract stimulates the immune system to recognize and attack cancer cells through activation of natural killer cells and other immune effectors. Used for Adjunctive treatment in various cancers (breast, colorectal, gastric, lung), Quality of life improvement in cancer patients.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}